Sm14 Vaccine Antigen Expression in Pichia Pastoris Without Methanol
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing recombinant Sm14 protein in industrial scales face challenges with stability and high production costs due to the reliance on methanol and inefficient expression systems, limiting large-scale production and purification.
Innovation Solution
A synthetic gene optimized for high expression in Pichia pastoris, using both the AOX1 and GAP promoters, combined with optimized codons and plasmids pPIC9K-Sm14-MV and pGAP9K-Sm14-MV, allows for efficient production and purification of Sm14 protein, eliminating the need for methanol and reducing production costs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If methanol-inducible promoter (AOX1) is used for protein expression in Pichia pastoris, then protein production can be achieved, but production costs increase and stability decreases due to reliance on methanol
Solution Approach 1:
The patent divides the promoter system into two separate functional components: AOX1 promoter for high-level inducible expression and GAP promoter for constitutive expression. This segmentation allows the system to leverage the high productivity of AOX1 when needed while using GAP for stable, methanol-free baseline production, thereby resolving the contradiction between productivity and ease of manufacture.
Solution Approach 2:
The patent changes the operational parameters of the expression system by introducing a dual-promoter configuration that allows switching between methanol-induced high-expression mode (AOX1) and methanol-free stable mode (GAP). This parameter change enables flexible control over production costs and stability while maintaining high productivity capabilities.
2Productivity
If synthetic gene with optimized codons is used, then expression efficiency increases, but system complexity increases due to multiple plasmids and promoters
Solution Approach 1:
The patent merges multiple functional elements (synthetic gene with optimized codons, AOX1 promoter, GAP promoter, and selection markers) into two integrated plasmid systems (pPIC9K-Sm14-MV and pGAP9K-Sm14-MV). This merging reduces the overall system complexity compared to using separate transformation steps while maintaining high expression efficiency through the combined action of both promoters.
3Quantity of substance
If protein is produced in inclusion bodies, then high concentration can be achieved, but additional purification steps are required reducing overall yield
Solution Approach 1:
The patent uses the GAP promoter as an intermediary mechanism that enables direct production of soluble, functional Sm14 protein without requiring inclusion body formation. This intermediary approach allows the protein to be produced in a naturally soluble state, eliminating the need for complex refolding and purification steps associated with inclusion bodies, thereby maintaining both high concentration and high overall yield.
Data Source
AI summary
The present invention is related to the recombinant production of proteins by using a synthetic gene for high protein expression in Pichia pastoris. More specifically, the invention describes the production of Sm14 Schistosoma mansoni recombinant protein, where a synthetic gene was created to promote high expression of such protein, a gene which was cloned under control of two types of Pichia pastoris promoters: methanol-inducible promoter (AOXI) and constituent promoter (GAP). With these constructions, Pichia pastoris strains were genetically manipulated to efficiently produce vaccine antigen Sm14. The processes to produce and purify this protein from P. pastoris cells, which can be escalated for their industrial production, were also improved.